Diagnostic of Lewy Body Dementia by Combining Scintigraphy (SPECT) Using a Specific Transporter and Magnetic Resonance Imaging (MRI)

Not Applicable

Completed

• Conditions: Lewy Body Dementia

• Registration Number: NCT00820937
• Lead Sponsor: University Hospital, Limoges

Brief Summary

The aim of this study is to improve the diagnostic of Lewy body dementia by combining the scintigraphy (SPECT) usig a spécific transporter and magnetic resonance imaging (MRI).

Detailed Description

Lewy body dementia is the second leading cause of dementia in France after degenerative Alzheimer's disease.

However its dignosis is difficult. Its comes in large part from the similarity of symptoms with another close dementia syndrome : the Alzheimer disease . Therfore, its is very important to have a mean to distinguish between the two dementias.

One highlight of the Lewy body dementia process being dopaminergic degeneration, the use of specific radioactive tracers is thought to be the way. The radiotracer that has the greatest advantage for these explorations is currently the DaTSCAN because it binds specifically on the dopamine transporter and can be used in Single photon emission computed tomography (SPECT).

The aim of this study is to improve the performance of imaging in the diagnosis of dementia by combining scintigraphy (SPECT) and magnetic resonance imaging (MRI) in the exploration of the striatal region . The development of this method applied to a population of subjects, with hallucinations and cognitive disorders, should demonstrate the value and complementarity of metabolic images (SPECT) and morphological (MRI) within the differential diagnosis of Lewy body dementia and the Alzheimer disease .

From a methodological point of view, the patient will be included in hospital and will have a clinical diagnosis defined according to the criteria of dementia NINCDS-ADRDA for the Alzheimer disease and Mc-Keith criteria for Lewy body dementia. Their MMSE will be over 18 and they have in common recurrent visual hallucinations.

After the inclusion, two steps must be distinguished, a neuropsychological evaluation stage and an scitigraphy exploration . Before the SPECT , all patients should have an MRI.

Study Timeline

• Study Start: 2006-03
• Primary Completion: 2008-03
• Study Completion: 2008-03
• Study First Submitted: 2008-12-27
• Study First Submitted QC: 2009-01-09
• Study First Posted: 2009-01-12
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-26
• Last Update Posted: 2009-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Patients with alzheimer disease following NINCDS-ADRDA scale or Lewy body dementia following Mc Keith scale.
• Aged between 65 et 90 years
• Patients with visual hallucination
• Patients with helping people
• Patients with MMSE (Mini Mental State Examination) equal or more than 18.
• Signed consent

Exclusion Criteria

• Hospitalized patients without their consent
• Patients who have not passed the neuropsychological tests
• Patients with a MMSE less than 18
• Patients without helping
• Patients with no visual hallucinations
• Patients with severe somatic pathology.
• Pregnancy
• Allergy to iodine

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
SPECT and MRI differential imaging	Visit 1

Secondary Outcome Measures

Name	Time	Method
Neuropsychological analysis	Visit 1

Trial Locations

Locations (3)

Département de Gérontologie - Chu Limoges; 🇫🇷 Limoges, France

Pôle de psychiatrie du sujet âgé - CH Esquirol; 🇫🇷 Limoges, France

Service de Neurologie - CHU de Limoges; 🇫🇷 Limoges, France